Chemomab Therapeutics (CMMB) Income from Discontinued Operations (2017 - 2019)
Chemomab Therapeutics (CMMB) posted Income from Discontinued Operations of 433000.0 for Q3 2019, down 411.51% on a QoQ basis from 139000.0 in Q2 2019, and down 736.76% year-over-year from 68000.0 in Q3 2018.
Chemomab Therapeutics (CMMB) Income from Discontinued Operations (2017 - 2019) Analysis & Trends
Chemomab Therapeutics' Income from Discontinued Operations history runs 3 years deep, the most recent figure standing at 433000.0 for Q3 2019.
- Quarterly Income from Discontinued Operations fell 736.76% year-over-year to 433000.0 in Q3 2019, while the trailing twelve-month figure through Sep 2019 was 6000.0 (down 98.95% YoY) and the FY2018 annual result came in at 621000.0, up 92.26% from the prior year.
- Income from Discontinued Operations was 433000.0 for Q3 2019 at Chemomab Therapeutics, down from 139000.0 in the prior quarter.
- Across five years, Income from Discontinued Operations topped out at 330000.0 in Q2 2018 and bottomed at 433000.0 in Q3 2019.
- A 3-year average of 72375.0 and a median of 126000.0 in 2017 frame the typical range for Income from Discontinued Operations.
- Peak annual rise in Income from Discontinued Operations reached 125.81% in 2019, while the deepest fall reached 736.76% in 2019.
- Chemomab Therapeutics' Income from Discontinued Operations stood at 113000.0 in 2017, then jumped by 41.59% to 160000.0 in 2018, then sank by 370.62% to 433000.0 in 2019.
- Business Quant data shows CMMB's Income from Discontinued Operations at 433000.0 in Q3 2019, 139000.0 in Q2 2019, and 140000.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.39 Bn | 467.60 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.08 Bn | 114.83 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | - |
| 10 | Chemomab Therapeutics | 714.32 Mn | 703.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | -433,000.00 |
| Jun 30, 2019 | 139,000.00 |
| Mar 31, 2019 | 140,000.00 |
| Dec 31, 2018 | 160,000.00 |
| Sep 30, 2018 | 68,000.00 |
| Jun 30, 2018 | 330,000.00 |
| Mar 31, 2018 | 62,000.00 |
| Dec 31, 2017 | 113,000.00 |